imatinib mylan 100mg film-coated tablets
mylan ireland limited unit 35/36, grange parade, baldoyle industrial estate, dublin 13, ireland - imatinib - film-coated tablet - imatinib 100 mg - antineoplastic agents
imatinib mylan 400mg film-coated tablets
mylan ireland limited unit 35/36, grange parade, baldoyle industrial estate, dublin 13, ireland - imatinib - film-coated tablet - imatinib 400 mg - antineoplastic agents
imatinib rowex 100mg film-coated tablets
rowex ltd newtown bantry, co. cork, , ireland - imatinib mesilate - film-coated tablet - imatinib mesilate 100 mg - antineoplastic agents
imatinib rowex 100mg film-coated tablets
rowex ltd - imatinib mesilate - film-coated tablet - 100 milligram(s) - protein kinase inhibitors; imatinib - protein-tyrosine kinase inhibitor - paediatric patients with newly diagnosed philadelphia chromosome (bcr-abl) positive (ph+) chronic myeloid leukaemia (cml) for whom bone marrow transplantation is not considered as the first line of treatment. paediatric patients with ph+ cml in chronic phase after failure of interferon-alpha therapy, or in accelerated phase or blast crisis. adult patients with ph+ cml in blast crisis. adult and paediatric patients with newly diagnosed philadelphia chromosome positive acute lymphoblastic leukaemia (ph+ all) integrated with chemotherapy. adult patients with relapsed or refractory ph+ all as monotherapy. adult patients with myelodysplastic/myeloproliferative diseases (mds/mpd) associated with platelet-derived growth factor receptor (pdgfr) gene re-arrangements. adult patients with advanced hypereosinophilic syndrome (hes) and/or chronic eosinophilic leukaemia (cel) with fip1l1-pdgfr rearrangement. adult patients with unresectable dermatofibrosarcoma protuberans (dfsp) and adult patients with recurre
imatinib rowex 400mg film-coated tablets
rowex ltd - imatinib mesilate - film-coated tablet - 400 milligram(s) - protein kinase inhibitors; imatinib - protein-tyrosine kinase inhibitor - paediatric patients with newly diagnosed philadelphia chromosome (bcr-abl) positive (ph+) chronic myeloid leukaemia (cml) for whom bone marrow transplantation is not considered as the first line of treatment. paediatric patients with ph+ cml in chronic phase after failure of interferon-alpha therapy, or in accelerated phase or blast crisis. adult patients with ph+ cml in blast crisis. adult and paediatric patients with newly diagnosed philadelphia chromosome positive acute lymphoblastic leukaemia (ph+ all) integrated with chemotherapy. adult patients with relapsed or refractory ph+ all as monotherapy. adult patients with myelodysplastic/myeloproliferative diseases (mds/mpd) associated with platelet-derived growth factor receptor (pdgfr) gene re-arrangements. adult patients with advanced hypereosinophilic syndrome (hes) and/or chronic eosinophilic leukaemia (cel) with fip1l1-pdgfr rearrangement. adult patients with unresectable dermatofibrosarcoma protuberans (dfsp) and adult patients with recurre
imatinib koanaa 100 mg film-coated tablets
koanaa healthcare limited - imatinib mesylate - film-coated tablet - 100 milligram(s) - protein kinase inhibitors; imatinib
imatinib koanaa 400 mg film-coated tablets
koanaa healthcare limited - imatinib mesylate - film-coated tablet - 400 milligram(s) - protein kinase inhibitors; imatinib
imatinib tad 100 mg film-coated tablets
tad pharma gmbh heinz-lohmann-strasse 5, 27472 cuxhaven, germany - film-coated tablet - imatinib mesilate 100 mg - antineoplastic agents
imatinib tad 400 mg film-coated tablets
tad pharma gmbh heinz-lohmann-strasse 5, 27472 cuxhaven, germany - film-coated tablet - imatinib mesilate 400 mg - antineoplastic agents
imatinib rowex 400mg film-coated tablets
rowex ltd newtown bantry, co. cork, , ireland - imatinib mesilate - film-coated tablet - imatinib mesilate 400 mg - antineoplastic agents